ZD 1839 in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep
growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to
die.
PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have
metastatic kidney cancer.